Forget Eli Lilly: These 2 Stocks Have More Upside

Forget Eli Lilly: These 2 Stocks Have More Upside

According to an analysis published by Motley Fool, Eli Lilly (NYSE: LLY) may not be the best option for investors seeking high returns. Despite the company's strong growth driven by its leading GLP-1 drugs (such as Mounjaro and Zepbound), its lofty valuation limits upside potential. Instead, the analysis highlights two competitor stocks with lower valuations and greater growth opportunities.

Recommendation Change

This is not a specific analyst rating change but a general market assessment suggesting investors may find better value in other stocks.

Analyst Rationale

Analysts believe that Pfizer (NYSE: PFE) has a diverse and strong product portfolio, along with a promising pipeline in obesity and diabetes treatments. Pfizer's current valuation is significantly lower than Eli Lilly's, providing a larger margin of safety. The other stock (not explicitly named in the summary) is likely Novo Nordisk (NVO) or another pharmaceutical company competing in the GLP-1 space.

Context

The market is focusing on GLP-1 drugs, which are seeing increasing demand for diabetes and obesity treatment. Eli Lilly has gained significantly due to its leadership in this area, but competition is intensifying as other companies enter. In contrast, Pfizer's stock has suffered due to declining COVID-19 product sales, leading to lower valuation multiples.

What to Make of It

While Eli Lilly remains a strong company, investors seeking higher upside may find more value in competitors like Pfizer, especially with promising pipelines and more attractive valuations. However, investors should assess the risks associated with each company before making any decisions.